|
WO2015058191A1
|
|
Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
|
|
EP3010500A1
|
|
Methods for identifying neuroprotective pkc activators
|
|
EP2776018A1
|
|
Pkc activators and combinations thereof
|
|
US2014323456A1
|
|
Esters of DCPLA and methods of treatment using the same
|
|
WO2013052922A1
|
|
Stimulus-elicited genomic profile markers of a neurodegenerative condition
|
|
EP2605773A1
|
|
Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
|
|
EP2539709A1
|
|
Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels
|
|
CA2776498A1
|
|
Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells
|
|
TW200942819A
|
|
Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)
|
|
WO2009005783A1
|
|
Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
|
|
WO2008143880A2
|
|
Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury
|
|
KR20140049054A
|
|
Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
|
|
CN101678080A
|
|
Bryostatin, bryostatin analog and other related substances to ischemia/in the curative effect of wind-induced memory impairment and brain injury
|
|
US2008160094A1
|
|
Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
|
|
CN101541322A
|
|
Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
|
|
EP1934618A2
|
|
Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
|
|
US2009029873A1
|
|
Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
|
|
CN101277691A
|
|
Use of a PKC activator, alone or combined with a pkc inhibitor to enhance long term memory
|
|
WO2007044094A1
|
|
Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
|
|
WO2007043998A1
|
|
Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
|
